PhaseBio Pharmaceuticals Inc (37) | License Agreements (5)
Recent Contracts
-
License Agreement, dated as of June 16, 2021, by and between PhaseBio Pharmaceuticals, Inc. and Alfasigma, S.p.A
(Filed With SEC on August 12, 2021)
-
Acknowledgement of Grant of a Sublicense in Accordance with the License Agreement between Medimmune Limited and PhaseBio Pharmaceuticals, Inc. and Related Options
(Filed With SEC on August 12, 2021)
-
Amendment to License Agreement, dated January 9, 2020, by and between PhaseBio Pharmaceuticals, Inc. and MedImmune Limited
(Filed With SEC on March 30, 2020)
-
Eighth Amendment to License Agreement, dated as of March 5, 2019, by and between PhaseBio Pharmaceuticals, Inc. and Duke University
(Filed With SEC on April 9, 2019)
-
License Agreement, dated April 1, 2019, by and between PhaseBio Pharmaceuticals, Inc. and Wacker Biotech GmbH
(Filed With SEC on April 9, 2019)
